会议
- 会议
- 视频
热门搜索：
一般內科/過敏免疫風濕科
台湾振兴医疗财团振兴医院
|
林孝義 醫師
Lin, Hsiao-Yi, M.D. FACR 學位 : 台北醫學院醫學士 進修 : 美國密西根大學風濕免疫科/臨床醫學中心 美國匹茲堡大學醫院/器官移植實驗室 現職 : 振興醫療財團法人振興醫院 一般內科/臨床試驗中心主任/一般醫學科主任 教職 : 國立陽明大學內科講師 副教授、臨床教授 經歷 : 美國密西根大學風濕免疫科/臨床醫學中心 臺北榮民總醫院內科總醫師、主治醫師、主任 專長學科 :痛風、嘌呤代謝、風濕病學、人類組織配合抗原 專科執照 : 中華民國內科專科醫師 (第0402號) 中華民國風濕病學會專科醫師 (第048號) 中華民國免疫學會專科醫師 (第070號) 美國風濕學院研究員(ACR Fellow 21893號) 參與民間團體：財團法人風濕病基金會 前執行長、董事 財團法人思源內科醫學研究發展基金會董事 財團法人腎臟病防治基金會董事 中華民國風濕病醫學會常務理事 中華民國思樂醫 (SLE)之友協會顧問 中華民國類風濕性關節炎(RA)之友協會創辦人 中華民國僵直性脊椎炎(AS)關懷協會創辦人 臺灣硬皮病友關懷協會(Scleroderma)創辦人 RA NarRAtive 國際倡議會議臺灣代表人 財團法人台灣藥物經濟暨效果研究學會 (TASPOR)常務理事 衛生福利部全民健康保險爭議審議會委員 Nature Reviews Rheumatology（中文版）編輯委員 International Journal of Rheumatic Diseases編輯委員 臺灣科技部審查委員 獎勵: 1991,1992,1994 國科會甲種獎 1992,1993,1996, 1999, 2000,2002, 2003, 2004, 2005, 2006, 2007, 2008,2009 台北榮民總醫院臨床教學績優獎 1993 台北市醫師公會第一屆杏林獎 2003,2004,2005,2006,2007,2008,2010 陽明大學醫學系網路票選優良老師 2014,2015.2010 臺北榮民總醫院醫教奉獻獎 2016 社團法人台灣中華民國風濕病醫學會大師獎 2017 振興醫院優良教師獎 REFERRED PAPER (in recent 5 years) Chang YW, Wong WW, Tsai HC, Chen YH, Kuo BS, Lynn Shugene, Lin HY et al.Anti- CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. 2019 NEJM (accepted) Wang CC, Lee SH, Lin HY, Liu FW, Chiou HJ, Chan RC, Chou CL. Short-term effect of ultrasound-guided low-molecular-weight hyaluronic acid injection on clinical outcomes and imaging changes in patients with rheumatoid arthritis of the ankle and foot joints. A randomized controlled pilot trial. 2017 Modern Rheumatology. Lang HC, Lee HC, Lee, SS, Lin HY, Chiu YM. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study. 2016 (published on line, IJRD) (IF:1.469) <Correspondent> YM Chiu, CH Tang, ST Hung,YW Yang,CH Fang, HY Lin. A real-world risk analysis of biological treatment (adalimumab and etanercept) in country with high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. 2016 Scandinavian Journal of Rheumatology. <Correspondent> HY Wang, CF Yang, Tj Chiou, JP G, HY Lin et al. Risk of hemophagocytic lymphohistiocytosis in adults with fevers of unknown origin: the clinical utility of a new scoring system on early detection. Hematological Oncology.(2016 online) Chien EJ, Hsu CH, Chang HJ, Lin HY* et al . In human T cells mifepristone antagonizes glucocorticoid non-genomic rapid responses in terms of Na+/H+-exchange 1 activity, but not ezrin/radixin/moesin phosphorylation. Online publication: steroids 19-JAN-2016 (IF:2.639) <Correspondent> Yu KH, Lai JH, Hsu PN, Chen DY ,Chen CJ , Lin HY. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: A randomized, open label, multicenter,allopurinol-controlled study. Scandinavian Journal of Rheumatology Published online: 15 Jan 2016 (IF:2.527) <Correspondent> Huang CC, Huang PH, Chen JH, Lan JL, Lin HY et al. An independent risk of Gout on development of deep vein thrombosis and pulmonary embolism: A Nationwide ,Population-Based Cohort Study. Medicine 2015;94:51. (IF:5.723) Wang CC, Chen MH, Lin HY. Effectiveness of Omalizumab therapy for atopic dermatitis – a preliminary report. Formosan Journal of Rheumatology 2015;29:10-16. (Non-SCI) Chen JH, Lan JL,Cheng CF, Lin HY et al. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study. J Rheumatol 2015 Sep; 42 (9) 1694-701. (IF:3.187) Hong JY, Lan TY , Tang GJ , Tang CH, Chen TJ, Lin HY*. Gout and the Risk of Dementia: A Nationwide Population-Based Cohort Study. Arthritis Research & Therapy 2015 17:139. (IF: 4.12) <Correspondent> Chiu YM, Lai MS, Lin HY, Lang HC, Lee LJ, Wang JD. Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. Clin Exp Rheumatol. 2014 Nov-Dec;32(6):898-903.(IF:2.973) Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P,Hussein H, Rahman MU. Risk of tuberculosis with anti-tumor necrosis factor-αtherapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis. 2014 Mar;17(3):291-8 (IF:1.771) Chen MH, Chou HP, Lai CC, Chen YD, Chen MH, Lin HY, Huang DF. Lung involvement in primary Sj?gren's syndrome: Correlation between high-resolution computed tomography score and mortality. J Chin Med Assoc. 2014 Feb;77(2):75-82.(IF:0.889) Chen MH, Huang ZM, Chang CW, Chen YA, Liu PC, Chen MH, Leu CM, Lin HY. Decoy receptor 3 suppresses B cell functions and has a negative correlation with disease activity in rheumatoid arthritis. Clinical and Experimental Rheumatology 2014 32(5):715-23. Epub 2014 Aug 1.(IF:2.973) <Correspondent> Chen YJ, Tseng JJ, Yang MC, Tsao YP, Lin HY. Acute respiratory distress syndrome in a pregnant woman with systemic lupus erythematosus: A case report. 2014 Lupus (IF:2.481) <Correspondent> Hsu CH, Chen MH, Chen WS, Lai CC, Lin HY. Relationship between the level of anti-double strand DNA antibody and relapse of lupus nephritis in patients with systemic lupus erythematosus. 2013 Formosan Journal of Rheumatology (Non-SCI) Chen JH, Lan JL, Yeh WT,Cheng CF, Chuang SY, Lin HY, Tsay GJ, Pan WH. Impact of Urate-Lowering Therapy on Long-term Risk of All-Cause and Cardiovascular Mortality in Gout Patients: Taiwanese Cohort Study. (J Rheum) Wang JC, Lin YC, Yang TF, Lin HY*. Ataxic sensory neuronopathy in a patientwith systemic lupus erythematosus. Lupus. 2012, 21: 905-9. (IF=2.783; R/C=12/29, Rheumatology) <Correspondent> Lin SZ, Chen CC, Lee KC, Tseng CW, Lin HY, Chen YC, Lin HC. DR-70 immunoassay for the surveillance of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012, 27: 547-52. (IF=3.325; R/C=22/74) Pongparadee C, Penserga E, Lee DJ, Chen SL, Gill RS, Hamid A, Kumthornthip W, Liu Y, Meliala L, Misbach HJ, Tan KH, Yeap SS, Yeo SN, Lin HY*. Current considerations for the management of musculoskeletal pain in Asian countries: a special focus on cyclooxygenase-2 inhibitors and non-steroid anti-inflammation drugs. Int J Rheum Dis. 2012 Aug;15(4):341-7. (IF:1.65; R/C=21/29, Rheumatology) Chang BC, Wang JY, Huang BS, Lin HY, Lee WCC. Dynamic impression insole in rheumatoid foot with metatarsal pain. Clin biomech. 2012, 27: 196-201. (IF=2.071; R/C=22/73, SPORT SCIENCES) Chen WS, Liu CY, Lee HT, Tsai K, Lin YC, Tarng DC, Ho CH, Lin HY*. Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients. Clin Rheumatol. 2012 Mar;31(3):469-77 (IF:2.037) Huang SF, Su WJ, Ruan SY, Yu CJ, Hsieh SC, Liu YC, Jan YJJ, Lin HY*.Risk factors for latent tuberculosis infection in RA patients treated with anti-tumor necrosis factor. Arthritis Research & Therapy 2012 Feb 14:P40 (IF: 4.12) Chen MH, Chen MH, Chen WS, Chang PM, Lee HT, Lin HY, Huang DF. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology. 2011, 50: 768-775. (IF=4.212; R/C=7/29, Rheumatology) Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Balfour A, Krammer G, Sallstig P, So A. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011, 70: 1264-71. (IF=9.111; R/C=1/29, Rheumatology) Clinical trial: D4300C00008 (Oskira): A Multi-Centre, Randomised, Double-Blind, Placebo?Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients with Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy. BEL-116301 (GSK): Observational Study of treatment, disease activity and flare in Systemic Lupus Erythematosus (SLE) in Asia Pacific A3921044 (Pfizer): Phase 3 randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of cp-690,550 in patients with active rheumatoid arthritis on background methotrexate ENIA11 (東生華): A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination with DMARDs versus DMARDs Alone in Patients with Rheumatoid Arthritis 5. A3921091 (Pfizer): Phase 3, Randomized, Double?Blind, Placebo?Controlled Study of the Efficacy and Safety of 2 Doses of TOFACITINIB (CP-690,550) or Adalimumab in subjects with Active Psoriatic Arthritis 6. A3921125 (Pfizer): Phase 3, Randomized, Double?Blind, Placebo?Controlled Study of the Efficacy and Safety of 2 Doses of TOFACITINIB (CP-690,550) in subjects with Active Psoriatic Arthritis and an Inadequate Response to at Least One TNF Inhibitor 7. A3921092 (Pfizer): A long-term,open-label extension study of tofacitinib (CP-690,550) for the treatment of psoriatic arthritis. 8. BI 655066 (百靈佳): A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with ankylosing spondylitis. 9. AB Science: A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1. methotrexate or to 2. any DMARD including at least one biologic drug if patients previously failed methotrexate or to 3. methotrexate in combination with any DMARD including biologic drugs. 10. A3921133 (Pfizer): Phase 3b/4 Randomized Safety Endpoint Study with An Efficacy Substudy of 2 Doses of Tofacitinib With and Without Methotrexate In Comparison To Adalimumab with Methotrexate in Subjects with Rheumatoid Arthritis. 11. A3921187 (Pfizer): A phase IIIB/IV Randomized double blind study of 5mg of tofacitinib with and without methotrexate in comparison to adalimumab with methotrexate in subjects with moderate to severely active rheumatoid arthritis. 12 . TLC599A1001: A Randomized, Open-lable, Parallel, PhaseI/II Single-Dose Administration Trial of TLC599 in Subjects with Osteoarthritis of the Knee. 13. GBL15-001: Mycophenolate mofetil versus Azathioprine for maintenance therapy of lupus nephritis. 14. Abbvie:生物製劑減量及暫緩續用對於類風濕性關節炎患者的臨床表現及醫療資源使用情況影響的病歷研究 15. A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects with Systemic Lupus Erythematosus. ... 更多 |
京公网安备 11011502002826号
